Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

TNI Biotech Expands Partnership with Hubei Qianjiang Pharma

publication date: Aug 13, 2014
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
TNI BioTech of Florida expanded its relationship with Hubei Qianjiang Pharma (SHA: 600568) by signing an agreement that will speed up development of IRT-101 (MENK). TNI discovered MENK, an immunotherapy for cancer and autoimmune diseases. In 2012, Qianjiang in-licensed China rights to the drug. According to TNI, the partnership combines the drug development expertise of its subsidiary Cytocom, with Qianjiang’s financial, manufacturing and distribution capabilities. More details....

Stock Symbol: (OTC: TNIB)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



ChinaBio® Events
Shanghai, China
April 15-16, 2015

>> More events...

Partner Events

China Healthcare Investment Conference
March 31 – April 2, 2015
Shanghai, China

Asia Biotech Invest 2015
May19-21, 2015
Hong Kong, China
>> More events...
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors